IDH1 and glioblastoma: Notably, TCGA-GBM samples including only IDH1-wild-type patients – distinguished with IDH1-mutant GBM in WHO classification of tumors 2016 – also showed similar patterns, suggesting that longer OS of favorable group did not simply arise from IDH1 pathogenic variant (Fig. 2a,b).